Loading…
Lobbying Income
$10K
Filings
3
Unique Clients
1
Active Period
2022
Registrant-reported income from clients on LDA filings
Largest clients by registrant-reported income
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
VALID Act of 2021
2022 · second_quarter · Client: Adaptive Biotechnologies Corp
2023 appropriations requests for NIH for T cell research in COVID19 and other disease areas; HR4128 and S2209 The VALID Act. Provisions related to first of a kind assays
Client expense: — · Firm income: $10,000
Matched citations: HR4128
2023 appropriations requests for NIH for T cell research in COVID19 and other disease areas; HR4128 and S2209 The VALID Act. Provisions related to first of a kind assays
Client expense: — · Firm income: $10,000
Matched citations: S2209
Consolidated Appropriations Act, 2022
2022 · first_quarter · Client: Adaptive Biotechnologies Corp
HR2471 Appropriations for NIH for T cell research in COVID19 and other disease areas; HR4128 and S2209 The VALID Act. Provisions related to first of a kind assays
Client expense: — · Firm income: —
Matched citations: HR2471
VALID Act of 2021
2022 · first_quarter · Client: Adaptive Biotechnologies Corp
HR2471 Appropriations for NIH for T cell research in COVID19 and other disease areas; HR4128 and S2209 The VALID Act. Provisions related to first of a kind assays
Client expense: — · Firm income: —
Matched citations: HR4128
HR2471 Appropriations for NIH for T cell research in COVID19 and other disease areas; HR4128 and S2209 The VALID Act. Provisions related to first of a kind assays
Client expense: — · Firm income: —
Matched citations: S2209
Territorial Tax Parity Act of 2021
2022 · first_quarter · Client: Adaptive Biotechnologies Corp
H.R. 1428, The VALID Act NIH Appropriations
Client expense: — · Firm income: —
Matched citations: H.R. 1428
Territorial Tax Parity Act of 2021
2022 · first_quarter · Client: Adaptive Biotechnologies Corp
H.R. 1428, The VALID Act NIH Appropriations
Client expense: — · Firm income: —
Matched citations: H.R. 1428
Territorial Tax Parity Act of 2021
2022 · first_quarter · Client: Adaptive Biotechnologies Corp
H.R. 1428, The VALID Act NIH Appropriations
Client expense: — · Firm income: —
Matched citations: H.R. 1428
Source: Senate LDA